Mastering Medical Device Equivalence: Key Requirements & EU MDR Compliance Strategy
Overview
Medical device equivalence is a regulatory mechanism under EU MDR (Regulation EU 2017/745) that allows manufacturers to demonstrate safety and performance by comparing their device to an existing predicate. To successfully claim equivalence under Annex XIV Part A (3) and MDCG 2020-5 guidance, manufacturers must establish complete technical, biological, and clinical equivalence. Under EU MDR rules, a valid equivalence claim requires full access to the equivalent device’s technical documentation via a formal contract or demonstrate identical manufacturing ownership to streamline Clinical Evaluation Reports (CER) and CE marking approval.
Contact Us
What is Medical Device Equivalence Under EU MDR?
Demonstrating medical device equivalence allows a manufacturer to prove that a new or modified device is comparable in safety, functionality, and performance to an already legally marketed device (the “equivalent device”). When executed correctly, an equivalence claim leverages existing clinical data to fulfill regulatory requirements, avoiding unnecessary clinical trials and reducing time-to-market.
Under the European Union Medical Device Regulation (EU MDR 2017/745), establishing equivalence requires rigorous comparative analysis across technical, biological, and clinical evaluations. The regulation strictly demands a direct, unbroken link between the subject device and the equivalent device, ensuring that safety profiles and clinical outcomes match without compromising patient health.
To understand how clinical data generated through equivalence fits into your overall European conformity roadmap, review our detailed guide on CE certification for medical devices under EU MDR.
The 3 Pillars of Medical Device Equivalence
To substantiate a regulatory claim under EU MDR Annex XIV Part A (3), MDCG 2020-5, and MEDDEV 2.7/1 rev. 4 guidance, manufacturers must demonstrate alignment across three core pillars:
| Pillar | Core Regulatory Assessment Criteria |
| Technical | Device design, operational principles, specifications, physical properties, deployment methods, and critical energy outputs. |
| Biological | Contact materials, cellular interactions, tissue contact duration, toxicological profiles, and leachables/extractables. |
| Clinical | Intended purpose, medical condition, anatomical site, user group, clinical performance, and risk/benefit ratio. |
Technical Equivalence: The subject device must share the same design, operational mechanics, physical and energy specifications, and deployment conditions as the equivalent device.
Biological Equivalence: Materials and chemical substances coming into contact with human tissues or body fluids must be identical or functionally comparable, ensuring biocompatibility and minimal toxicological risk.
Clinical Equivalence: The device must serve the same clinical indication, target the same anatomical site, perform the same medical function in the same patient population, and deliver equivalent clinical outcomes.
Key Regulatory Requirements for Demonstrating Equivalence
Establishing a legally defensible medical device equivalence claim under current MDR guidelines requires adherence to strict criteria:
Strict Characteristic Alignment: Every technical, biological, and clinical specification must be evaluated and aligned with the equivalent device using the standardized table framework from MDCG 2020-5 Annex I.
No “Pick-and-Choose” Data Combination: Regulators explicitly prohibit combining traits from multiple devices to construct a single “composite” equivalent device. Equivalence must be established against one single, identifiable predicate device.
Direct Access to Technical Documentation: Under EU MDR Article 61(5), if the equivalent device is manufactured by a third party, the manufacturer claiming equivalence must have a signed contract allowing full access to the predicate’s technical documentation.
Robust Post-Market Surveillance (PMS) Integration: Real-world safety and post-market clinical follow-up (PMCF) data from the equivalent device must be integrated into the Clinical Evaluation Report (CER) to prove sustained safety over time.
Common Mistakes to Avoid in Equivalence Claims
Navigating equivalence under EU MDR is far more restrictive than under the former MDD directive. Manufacturers often make critical errors that lead to Notified Body rejection:
| Common Equivalence Mistake | MDR Solution |
| Unjustified Differences | Provide clear scientific justification and risk assessment for any design, dimensional, or material variation. |
| Mixing Multiple Predicates | Avoid combining traits from different products. Focus the clinical evaluation strictly on one identical equivalent device. |
| Lack of Technical Access | Secure a binding legal contract for full access to technical files or use your own proprietary predicate device. |
- Ignoring Minor Differences: Failing to scientifically justify slight variations in material formulation, surface coating, or dimensions often invalidates the claim.
Relying on Public Datasheets: Using marketing brochures or public sales material to prove technical or biological equivalence is insufficient for Notified Body approval. Full technical documentation or proprietary testing data is mandatory.
Combining Device Attributes: Attempting to cite Device A for technical traits and Device B for clinical outcomes is non-compliant.
For manufacturers evaluating whether to claim equivalence or pursue an alternative pathway, explore our guide on selecting FDA regulatory pathways for new medical devices when planning multi-jurisdiction submissions.
Unsure if your predicate device meets EU MDR technical criteria
Consult Operon Strategist’s regulatory team for a complete equivalence feasibility review
How Operon Strategist Accelerates Regulatory Approvals & Equivalence Strategy
Navigating complex medical device equivalence assessments, technical file preparation, and global market approvals requires seasoned regulatory oversight. Operon Strategist offers comprehensive medical device consulting services to ensure seamless compliance across major international authorities:
CE Marking & EU MDR Technical Documentation: Structuring complete technical files, General Safety and Performance Requirements (GSPR), and Clinical Evaluation Reports (CER) via our specialized CE marking for medical devices consulting.
US FDA 510(k) Submissions & Predicate Matching: Assisting medical device sponsors with substantial equivalence demonstrations, eSTAR filings, and pre-sub meetings through our FDA 510(k) consultant services.
CDSCO Import Licensing & Market Entry: Managing Indian Authorized Agent (IAA) representation and import registrations via our dedicated CDSCO registration consulting services.
Global Turnkey & Quality Management Systems: Designing cleanrooms, facility layouts, and audit-ready Quality Management Systems in full compliance with ISO 13485, US FDA QMSR, and MDSAP standards.
Need assistance authoring your Clinical Evaluation Report (CER)
Connect with Operon Strategist today
FAQ's
What is medical device equivalence under EU MDR?
Medical device equivalence is a regulatory process of demonstrating that a subject device shares identical technical, biological, and clinical characteristics with a legally marketed predicate device to support clinical safety without new trials.
Can I combine features from two different devices to claim equivalence?
No. Under EU MDR and MDCG 2020-5 guidelines, equivalence must be established against a single, specific predicate device; combining attributes from multiple devices is strictly prohibited.
What are the three pillars of equivalence?
The three pillars are Technical equivalence (design and performance), Biological equivalence (materials and tissue contact), and Clinical equivalence (intended purpose and clinical outcomes).
Is a legal contract required to claim equivalence with another company's device?
Yes. Under EU MDR Article 61(5), if you reference a third-party device for equivalence, you must have a formal agreement granting full, ongoing access to its technical documentation.
What happens if equivalence cannot be proven?
If equivalence cannot be established due to data gaps or technical differences, the manufacturer must conduct independent clinical investigations or alternative clinical evaluations to achieve CE marking.